Press Releases
  Date Title View
Feb 7, 2017
SAN DIEGO, Feb. 07, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced the appointment of William R. LaRue as an additional independent member to the Conatus Board of Directors. Mr. LaRue also will serve as Chair of the Audit Committee. "We are pleased to strengthen our Board of Dir...
Feb 6, 2017
SAN DIEGO, Feb. 06, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company's programs and outlook at the Biotechnology Industry Organization (BIO) CEO & Investor Conference in New York at 2:30 p.m. ET on Monday, February 13, 2017. An ...
Feb 2, 2017
SAN DIEGO , Feb. 02, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) announced today the promotion of Daniel L. Ripley to Senior Vice President, Business Development, Program and Alliance Management, effective immediately. Mr. Ripley will continue to lead licensing and partnering initiatives and act...
Dec 19, 2016
- Conference Call and Webcast Presentation at 5:30 p.m. ET Today - - Continuing Initial Focus on NASH Cirrhosis with Parallel Development in NASH Fibrosis - - Full Funding in Position for Remaining Development of E...
Nov 14, 2016
- Emricasan Improves Liver Function in Cirrhosis Patients with NASH and/or Elevated MELD Scores - - Emricasan Improves Hepatic Blood Flow, Portal Hypertension, and Liver Function in Animal Models - SAN DIEGO , Nov. 14, 2016 (GLOBE NEWSWIRE...
Nov 9, 2016
SAN DIEGO, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company's programs and outlook at the Stifel 2016 Healthcare Conference in New York at 8:45 a.m. ET on Wednesday, November 16, 2016. An au...
Nov 8, 2016
SAN DIEGO, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and nine months ended September 30, 2016, and provided updates on its clini...
Nov 3, 2016
SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced the initiation of ENCORE-PH (PH for Portal Hypertension), a randomized, double-blind, placebo-controlled, Phase 2b clinical trial evaluating emricasan, the company's first-in-class, orally-active pan-caspase inhibitor, in a...
Nov 1, 2016
SAN DIEGO, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the third quarter ended September 30, 2016, after the market clos...
Oct 3, 2016
Emricasan Improves Liver Function in Cirrhosis Patients with NASH and/or Elevated MELD Scores Emricasan Improves Hepatic Blood Flow, Portal Hypertension, and Liver Function in Animal Models SAN DIEGO, Oct. 03, 2016 (GLOBE NEWSWIRE) -- Con...
FirstPrevious
2
...
NextLast
= add release to Briefcase